Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

4605 - Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non small cell lung cancer (NSCLC) treated with osimertinib: results from two Phase II studies


09 Sep 2017


Poster display session


Cytotoxic Therapy;  Cancers in Adolescents and Young Adults (AYA);  Targeted Therapy;  Non-Small Cell Lung Cancer


Tetsuya Mitsudomi


Annals of Oncology (2017) 28 (suppl_5): v460-v496. 10.1093/annonc/mdx380


T. Mitsudomi1, M. Ahn2, L.2. Bazhenova3, F. Blackhall4, T. Hida5, M. Majem Tarruella6, S.L. Vowler7, G. Laus8, P.A. Jänne9, J.C. Yang10

Author affiliations

  • 1 Thoracic Surgery, Kindai University School of Medicine, 577-8502 - Osaka/JP
  • 2 Samsung Medical Center, Sungkyunkwan University School of Medicine, 135-710 - Seoul/KR
  • 3 Uc San Diego Health, Moores Cancer Center, San Diego/US
  • 4 The Christie Nhs Foundation Trust And Division Of Molecular And Clinical Cancer Services, University of Manchester, M20 4BX - Manchester/GB
  • 5 Department Of Thoracic Oncology, Aichi Cancer Center, 464-8681 - Nagoya/JP
  • 6 Medical Oncology, Hospital de la Santa Creu i Sant Pau, 8026 - Barcelona/ES
  • 7 Biostatistics And Informatics, AstraZeneca, Cambridge/GB
  • 8 Global Medicines Development, AstraZeneca, Cambridge/GB
  • 9 Lowe Center For Thoracic Oncology, Dana Farber Cancer Institute  , Boston, MA/US
  • 10 Cancer Research Center, National Taiwan University, Taipei/TW


Abstract 4605


Osimertinib is an oral, potent, CNS active, irreversible EGFR-TKI approved to treat pts with T790M-positive advanced NSCLC. Here we present updated data from a pre-planned pooled analysis of Phase II studies: AURA extension (NCT01802632), AURA2 (NCT02094261).


Pts with centrally confirmed T790M-positive (by cobas® EGFR Mutation Test) advanced NSCLC, who had progressed following EGFR-TKI treatment, received osimertinib 80 mg once daily. Other inclusion criteria were measurable disease, WHO performance status 0/1 and acceptable organ function. Pts with stable CNS metastases were eligible. The primary efficacy endpoint was objective response rate (ORR) by RECIST 1.1 per blinded independent central review (BICR). Secondary endpoints included duration of response (DoR), progression-free survival (PFS), OS and safety.


As of the 1 Nov 2016 data cut-off (DCO) 411 pts had received osimertinib (129 pts as second-line and 282 pts as ≥third-line); median treatment exposure was 16.4 months (mo; range 0–29.7 mo). Pooled results (BICR) were: ORR (evaluable for response set; EFR), 66% (95% confidence interval [CI] 61, 70); median DoR (EFR), 12.3 mo (95% CI 11.1, 13.8); median PFS (full analysis set), 9.9 mo (95% CI 9.5, 12.3). At DCO, 188 pts (46%) had died, 191 pts (47%) remained in survival follow up, and 32 pts (8%) had discontinued before death. Pooled median OS was 26.8 mo (95% CI 24.2, not calculable [NC]); median OS in the second-line and ≥third-line cohorts (95% CI) was 25.8 mo (24.0, NC) and NC (22.1, NC), respectively. The 12 and 24 mo survival rates were 80% and 56%, respectively. The most common (investigator assessed) possibly causally-related adverse events (AEs) were rash (grouped term 42%, [grade ≥3, 1%]) and diarrhoea (39% [


With a median treatment exposure of 16.4 mo, osimertinib resulted in a median OS of 26.8 mo. This pooled analysis represents the most mature clinical trial data for osimertinib in pts with pre-treated T790M positive advanced NSCLC, and further establishes osimertinib as standard of care in this setting.

Clinical trial identification

AURA extension (NCT01802632), AURA2 (NCT02094261)

Legal entity responsible for the study





T. Mitsudomi: Honoraria: AstraZeneca, Boehringer- Ingelheim, Chugai Research grant: Boehringer-Ingelheim, Chugai. L. Bazhenova: Advisory board: AstraZeneca. F. Blackhall: Honoraria: AstraZeneca, Pfizer, Boehringer Ingelheim, Medivation, Novartis, MSD, BMS Consulting/Advisory role: Medivation, Roche. Research funding: AstraZeneca, Pfizer, Boehringer Ingelheim, Medivation, Novartis, MSD, BMS. Expense: Boehringer Ingelheim. T. Hida: Research funding and honoraria: Chugai Pharmaceutical, Novartis Pharma, Taiho Pharmaceutical, AstraZeneca, Nippon Boehringer Ingelheim, Clovis Oncology, Astellas. M. Majem Tarruella: Advisory Board: Novartis, Roche, Pfizer, Bristol-Myers Squibb, Boehringer Ingelheim. S.L. Vowler, G. Laus: Employee of AstraZeneca. P.A. Jänne: AstraZeneca – consulting and sponsored research Boehringer Ingelheim – consulting Pfizer – consulting Roche/Genentech – consulting Chugai Pharmaceuticals – consulting ARIAD – consulting Astellas – sponsored research. J.C-H. Yang: Honorarium/Ad board: Boehringer Ingelheim, Eli Lilly, Bayer, Roche/Genentech/Chugai, Astellas, MSD, Merck Serono, Pfizer, Novartis, Clovis Oncology, Celgene, Merrimack, Yuhan Pharma, BMS, Ono pharma Daiichi Sankyo, AstraZeneca, Hansoh Pharmaceuticals. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.